Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "An Update on Pharmacogenomic and Pharmacogenetic Challenges in Cardiovascular Diseases and Psychiatric Disorders"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: 15 September 2023 | Viewed by 213
Special Issue Editor
Interests: pharmacogenetics; pharmacogenomics; genetics of complex traits; epigenetics
Special Issue Information
The first draft of the human genome was published a little more than 20 years ago. One of the main promises was to make it possible to personalize drug therapy, increasing safety and clinical efficacy in many different clinical settings. After 20 years, the costs have lowered substantially, and there are several examples of the use of pharmacogenetics in clinics, but some areas show more advances than others. While cancer therapy is very advanced, showing even new treatments developed for specific mutations in tumoral tissue, there are few examples in cardiovascular and psychiatric areas that are of clinical importance today. However, there is huge potential to uncover new pharmacogenetic targets and, in doing so, help to shed light on new drug targets and pathogenesis mechanisms that are still poorly understood. It is very interesting that cardiovascular morbidity increases the risk of psychiatric disorders and the reverse is also true. So, it is possible that common mechanisms may be involved in both diseases.
We are pleased to invite you to contribute with manuscripts in cardiovascular or psychiatric pharmacogenetics and pharmacogenomics research. This special Issue aims to publish a collection of articles regarding new candidate genes, genome-wide analysis and pharmacogenetic and genomic data that may help to better understand the dynamics between altered pathways and predisposition to disease and the clinical failure of drug therapies in cardiovascular and psychiatric diseases.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following: genomic-wide data, candidate genes as vascular endothelial growth factor, matrix metalloproteinases, adipokines, brain derived neurotrophic factor, or pathways involved in oxidative stress, blood–brain barrier dynamics (or other membrane barriers), neuroinflammation, corticoid signaling affecting cardiovascular disease or psychiatric disorders and drug therapy.
I look forward to receiving your contributions.
Dr. Riccardo Lacchini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cardiovascular disease
- psychiatric disorders
- gene polymorphisms
- oxidative stress
- endocrine factors